Who are Stoke Therapeutics, Inc.'s main suppliers?

Stoke Therapeutics, Inc. (STOK) key suppliers include: NWALP-PHOP-PROPERTY-OWNER-LLC, ACADIA Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc., ORANY, ORANY. View the full supplier network at chainsifter.com/chain/STOK.

Who are Stoke Therapeutics, Inc.'s major customers?

Stoke Therapeutics, Inc. (STOK) key customers include: BIOGEN-INTERNATIONAL-GMBH, ACADIA Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc., Myriad Genetics, Inc., Myriad Genetics, Inc. and 3 more. View the full customer network at chainsifter.com/chain/STOK.

What sector is Stoke Therapeutics, Inc. in?

Stoke Therapeutics, Inc. (STOK) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Stoke Therapeutics, Inc. Supplier List (STOK): 5 Verified Suppliers

5Suppliers

8Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Stoke Therapeutics, Inc. (STOK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships

3Distinct source URLs

4High confidence

0.764Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Stoke Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
NWALP-PHOP-PROPERTY-OWNER-LLC	NWALP-PHOP-PROPERTY-OWNER-LLC	92%	On January 21, 2026, Stoke Therapeutics, Inc. (the "Company") entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC
ACAD	ACADIA Pharmaceuticals Inc.	72%	ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…
ACAD	ACADIA Pharmaceuticals Inc.	72%	Reciprocal relationship from ACAD graph: 2023 as there is no alternative use for the asset. In January 2022, the Company entered into a license and collaboration agreement with Stoke Therapeutics, In…
ORANY	ORANY	72%	ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from STOK graph: ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional i…

Stoke Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
BIOGEN-INTERNATIONAL-GMBH	BIOGEN-INTERNATIONAL-GMBH	92%	In connection with the closing of this transaction in February 2025, the Company received an upfront payment of $ 165.0 million and is eligible to receive development and commercial milestone payment…
ACAD	ACADIA Pharmaceuticals Inc.	72%	Reciprocal relationship from ACAD graph: Reciprocal relationship from STOK graph: ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional in…
ACAD	ACADIA Pharmaceuticals Inc.	72%	ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from STOK graph: expire by the other party. Any such termination or expiration would adversely affect us financially and could harm ou…
MYGN	Myriad Genetics, Inc.	72%	expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation. Risks Related to our Financial Position We have a history o…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from STOK graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from STOK graph: ntinue to expand and strengthen o…
ORANY	ORANY	72%	ntinue to expand and strengthen our network of third-party providers but may also consider investing in additional internal manufacturing capabilities in the future if there is a technical need, or a…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	her related breaches. Our employees, principal investigators, CROs, CMOs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and …

Stoke Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
STOK-DEBT	Debt stack $3.4M	90%	Market cache reports total debt of $3.4M.

Stoke Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
STOK-OWNER-MORGAN-STANLEY	MORGAN STANLEY	90%	13F overlay lists MORGAN STANLEY as top holder; 198 tracked holders.

Stoke Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BIAF	bioAffinity Technologies, Inc.	100.00	2
KDK	Kodiak AI, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
ATYR	aTyr Pharma, Inc.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
GH	Guardant Health, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
ELVN	Enliven Therapeutics, Inc.	100.00	2
GHRS	GH Research PLC	100.00	2
IMNM	Immunome, Inc.	100.00	2
TPST	Tempest Therapeutics, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
BNTC	Benitec Biopharma Inc.	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
DSGN	Design Therapeutics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
TEM	Tempus AI, Inc.	100.00	2

Stoke Therapeutics, Inc. Supply Chain